Skip to main content

Table 2 Univariate analyses of predictors for radiographic progression

From: Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT

  Placebo-treated patients Adalimumab-treated patients All patients
  OR 95% CI Pvalue OR 95% CI Pvalue OR 95% CI Pvalue
Treatment with adalimumaba NA NA NA NA NA NA 0.24 0.13, 0.48 < 0.001
CRP (time-averaged) 1.74 1.33, 2.28 < 0.001 1.48 0.99, 2.22 0.058 1.84 1.47, 2.30 < 0.001
CRP (continuous) 1.40 1.12, 1.75 0.003 1.05 0.84, 1.31 0.684 1.18 1.03, 1.35 0.017
CRP > 0.287 mg/dla 5.50 1.59, 19.09 0.007 3.12 0.39, 25.02 0.285 4.25 1.47, 12.24 0.007
CRP (1.0 mg/dla 3.98 1.90, 8.32 < 0.001 3.51 1.08, 11.39 0.036 3.82 2.09, 6.99 < 0.001
CRP (2.0 mg/dla 4.40 2.05, 9.45 < 0.001 1.34 0.34, 5.23 0.676 3.46 1.87, 6.42 < 0.001
Age 1.00 0.97, 1.03 0.954 1.02 0.97, 1.07 0.399 1.01 0.98, 1.04 0.484
RF-positivea 1.45 0.46, 4.60 0.530 1.65 0.33, 8.27 0.542 1.41 0.57, 3.49 0.458
Swollen joint count 1.02 0.99, 1.06 0.122 1.01 0.97, 1.06 0.657 1.02 1.00, 1.04 0.100
Tender joint count 1.00 0.98, 1.02 0.741 1.01 0.98, 1.04 0.459 1.01 0.99, 1.02 0.358
mTSS 1.03 1.01, 1.04 < 0.001 1.00 0.995, 1.01 0.365 1.01 1.00, 1.02 0.001
Joint erosion 1.05 1.02, 1.08 < 0.001 1.01 0.99, 1.02 0.490 1.02 1.01, 1.03 0.001
Joint space narrowing 1.05 1.03, 1.08 < 0.001 1.01 0.99, 1.03 0.264 1.02 1.01, 1.04 0.001
Methotrexate (yes)a 1.37 0.67, 2.77 0.387 2.15 0.63, 7.33 0.222 1.47 0.82, 2.64 0.201
PsA duration 1.00 0.96, 1.04 0.816 1.03 0.97, 1.10 0.337 1.00 0.97, 1.04 0.896
Psoriasis duration 0.97 0.93, 0.998 0.039 1.03 0.99, 1.08 0.140 0.99 0.96, 1.01 0.277
Weight 1.01 0.99, 1.03 0.450 1.00 0.97, 1.03 0.848 1.00 0.99, 1.02 0.717
  1. CI, confidence interval; CRP, C-reactive protein; mTSS, modified total Sharp score; NA, not applicable; OR, odds ratio; PsA, psoriatic arthritis; RF, rheumatoid factor. All variables are at baseline, except CRP (time-averaged). aDichotomous variables - those without a footnote annotation are continuous variables.